Investor Carl Icahn threatened a proxy fight if Amylin Pharmaceuticals' board won't put the company up for sale. Icahn, an Amylin shareholder, criticized the board for not commenting on media reports that it had rejected a takeover bid from Bristol-Myers Squibb, as well as for allowing a public offering of 10% of the firm without indicating Bristol's bid in the registration statement. An Amylin spokesman said Icahn's allegations have no merit and that the board "is fully aware of its fiduciary duties and is committed to always acting in the best interests of all stockholders."

Full Story:

Related Summaries